Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Alessia Bianchi, Rosa Cortese, Ferran Prados, Carmen Tur, Baris Kanber, Marios C Yiannakas, Rebecca Samson, Floriana De Angelis, Lise Magnollay, Anu Jacob, Wallace Brownlee, Anand Trip, Richard Nicholas, Yael Hacohen, Frederik Barkhof, Olga Ciccarelli, Ahmed T Toosy
BACKGROUND: Optic neuritis (ON) is a common feature of inflammatory demyelinating diseases (IDDs) such as multiple sclerosis (MS), aquaporin 4-antibody neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). However, the involvement of the optic chiasm (OC) in IDD has not been fully investigated. AIMS: To examine OC differences in non-acute IDD patients with (ON+) and without ON (ON-) using magnetisation transfer ratio (MTR), to compare differences between MS, AQP4 + NMOSD and MOGAD and understand their associations with other neuro-ophthalmological markers...
April 22, 2024: Multiple Sclerosis: Clinical and Laboratory Research
#2
JOURNAL ARTICLE
Miguel Leal Rato, Bo Chen, Anna Francis, Silvia Messina, Madalina Miron, Yvonne Sharawakanda, Eoin O'Sullivan, Sarah Cooper, Leonora Fisniku, Christopher Halfpenny, Roswell Martin, Jeremy Hobart, Waqar Rashid, Cheryl Hemingway, Victoria Williams, Yael Hacohen, Ruth Dobson, Sithara Ramdas, Maria Isabel Leite, Jacqueline Palace, Ruth Geraldes
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare disorders often seen in highly specialized services or tertiary centres. We aimed to assess if cohort characteristics depend on the origin of the referral catchment areas serviced by our centre (i.e. local, regional or national). METHODS: Retrospective cohort study using a national referral service database including local (Oxfordshire), regional (Oxfordshire and neighbouring counties), and national patients...
March 14, 2024: Multiple Sclerosis and related Disorders
#3
JOURNAL ARTICLE
Mohammad Kurd, Li-Tal Pratt, Tal Gilboa, Aviva Fattal-Valevski, Adi Vaknin-Dembinsky, Avi Gadoth, Yael Hacohen, Hadas Meirson
OBJECTIVE: To validate the recently published diagnostic criteria for Myelin Oligodendrocyte Glycoprotein-antibody associated disease (MOGAD) in real-world cohort of children with acquired demyelinating syndromes. METHODS: Patients <18yrs presenting with demyelinating disease to Pediatric neuroimmunology clinics at two Israeli tertiary centers who had MOG antibodies (MOG-Abs) tested between 01/07/2017 and 15/08/2023 were included. Diagnostic criteria for MOGAD were applied and sensitivity and specificities were calculated...
January 23, 2024: European Journal of Paediatric Neurology: EJPN
#4
JOURNAL ARTICLE
Omar Abdel-Mannan, Dimitrios Champsas, Carmen Tur, Vanessa Lee, Sharmila Manivannan, Haroon Usman, Alison Skippen, Ishita Desai, Manali Chitre, Rob Forsyth, Rachel Kneen, Dipak Ram, Sithara Ramdas, Thomas Rossor, Siobhan West, Sukhvir Wright, Jacqueline Palace, Evangeline Wassmer, Cheryl Hemingway, Ming J Lim, Kshitij Mankad, Olga Ciccarelli, Yael Hacohen
BACKGROUND: Lesion resolution is often observed in children with myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and asymptomatic lesions are less commonly reported in MOGAD than in multiple sclerosis (MS). OBJECTIVE: We aimed to evaluate brain MRI changes over time in paediatric MOGAD. METHODS: Retrospective study in eight UK paediatric neuroscience centres. Acute brain MRI and available follow-up MRIs were reviewed...
November 18, 2023: Journal of Neurology, Neurosurgery, and Psychiatry
#5
JOURNAL ARTICLE
Itay Lotan, John J Chen, Yael Hacohen, Omar Abdel-Mannan, Sara Mariotto, Saif Huda, Emily Gibbons, Adi Wilf-Yarkoni, Mark A Hellmann, Hadas Stiebel-Kalish, Sean J Pittock, Eoin P Flanagan, Negar Molazadeh, Monique Anderson, Rebecca Salky, Gabriela Romanow, Patrick Schindler, Ankelien Solveig Duchow, Friedemann Paul, Michael Levy
BACKGROUND: The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown. OBJECTIVE: The objective was to describe the outcomes of IVIG treatment for acute MOGAD attacks. METHODS: A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients' demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before the attack, at the nadir of the attack before IVIG treatment, and at follow-up visits ⩾3 months after treatment...
August 2023: Multiple Sclerosis: Clinical and Laboratory Research
#6
EDITORIAL
Yael Hacohen, Carmen Tur
No abstract text is available yet for this article.
July 25, 2023: Neurology
#7
JOURNAL ARTICLE
Susana Otero-Romero, Christine Lebrun-Frénay, Saúl Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintoré
BACKGROUND AND PURPOSE: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. We aimed to develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). METHODS: This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions and outcomes) considered all authorized DMTs and vaccines...
August 2023: European Journal of Neurology
#8
REVIEW
Susana Otero-Romero, Christine Lebrun-Frénay, Saúl Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintoré
BACKGROUND: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. OBJECTIVE: To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). METHODS: This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs and vaccines...
July 2023: Multiple Sclerosis: Clinical and Laboratory Research
#9
JOURNAL ARTICLE
Ayelet Zerem, Stephanie Libzon, Liat Ben Sira, Hadas Meirson, Moran Hausman-Kedem, Noam Haviv, Keren Yosovich, Adi Mory, Hagit Baris Feldman, Dorit Lev, Tally Lerman-Sagie, Aviva Fattal-Valevski, Yael Hacohen, Daphna Marom
BACKGROUND: Leukodystrophies are monogenic disorders primarily affecting the white matter. We aimed to evaluate the utility of genetic testing and time-to-diagnosis in a retrospective cohort of children with suspected leukodystrophy. METHODS: Medical records of patients who attended the leukodystrophy clinic at the Dana-Dwek Children's Hospital between June 2019 and December 2021 were retrieved. Clinical, molecular, and neuroimaging data were reviewed, and the diagnostic yield was compared across genetic tests...
May 27, 2023: European Journal of Paediatric Neurology: EJPN
#10
JOURNAL ARTICLE
Nee Na Kim, Omar Abdel-Mannan, James Davidson, Pascale Du Pre, Rachel Kneen, Kshitij Mankad, Yael Hacohen
We report two children with molecularly confirmed mitochondrial disease mimicking Neuromyelitis Optica Spectrum Disorder (NMOSD). The first patient presented at the age of 15 months with acute deterioration following a pyrexial illness with clinical features localising to the brainstem and spinal cord. The second patient presented at 5 years with acute bilateral visual loss. In both cases, MOG and AQP4 antibodies were negative. Both patients died within a year of symptoms onset from respiratory failure. Arriving at an early genetic diagnosis is important for redirection of care and avoiding potentially harmful immunosuppressant therapies...
June 2023: Multiple Sclerosis: Clinical and Laboratory Research
#11
JOURNAL ARTICLE
Vyanka Redenbaugh, Nicholas H Chia, Laura Cacciaguerra, Jennifer A McCombe, Jan-Mendelt Tillema, John J Chen, A Sebastian Lopez Chiriboga, Elia Sechi, Yael Hacohen, Sean J Pittock, Eoin P Flanagan
BACKGROUND: Magnetic resonance imaging (MRI) T2-lesions resolve more often in myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) than aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and multiple sclerosis (MS) in adults but few studies analyzed children. OBJECTIVE: The main objective of this study is to investigate MRI T2-lesion evolution in pediatric MOGAD, AQP4 + NMOSD, and MS. METHODS: Inclusion criteria were as follows: (1) first clinical attack; (2) abnormal MRI (⩽6 weeks); (3) follow-up MRI beyond 6 months without relapses in that region; and (4) age < 18 years...
June 2023: Multiple Sclerosis: Clinical and Laboratory Research
#12
JOURNAL ARTICLE
Nicholas M Allen, Mark O'Rahelly, Bruno Eymard, Mondher Chouchane, Andreas Hahn, Gerry Kearns, Dae-Seong Kim, Shin Yun Byun, Cam-Tu Emilie Nguyen, Ulrike Schara-Schmidt, Heike Kölbel, Adela Della Marina, Christiane Schneider-Gold, Kathryn Roefke, Andrea Thieme, Peter Van den Bergh, Gloria Avalos, Rodrigo Álvarez-Velasco, Daniel Natera-de Benito, Man Hin Mark Cheng, Wing Ki Chan, Hoi Shan Wan, Mary Ann Thomas, Lauren Borch, Julie Lauzon, Cornelia Kornblum, Jens Reimann, Andreas Mueller, Thierry Kuntzer, Fiona Norwood, Sithara Ramdas, Leslie W Jacobson, Xiaobo Jie, Miguel A Fernandez-Garcia, Elizabeth Wraige, Ming Lim, Jean Pierre Lin, Kristl G Claeys, Selma Aktas, Maryam Oskoui, Yael Hacohen, Ameneh Masud, M Isabel Leite, Jacqueline Palace, Darryl De Vivo, Angela Vincent, Heinz Jungbluth
In utero exposure to maternal antibodies targeting the fetal acetylcholine receptor isoform (fAChR) can impair fetal movement, leading to arthrogryposis multiplex congenita (AMC). fAChR antibodies have also been implicated in apparently rare, milder myopathic presentations termed fetal acetylcholine receptor inactivation syndrome (FARIS). The full spectrum associated with fAChR antibodies is still poorly understood. Moreover, since some mothers have no myasthenic symptoms, the condition is likely underreported, resulting in failure to implement effective preventive strategies...
May 15, 2023: Brain
#13
JOURNAL ARTICLE
John J Chen, Eoin P Flanagan, Sean J Pittock, Nicole Caroline Stern, Nanthaya Tisavipat, M Tariq Bhatti, Kevin D Chodnicki, Deena A Tajfirouz, Sepideh Jamali, Amy Kunchok, Eric R Eggenberger, Marie A Di Nome, Elias S Sotirchos, Eleni S Vasileiou, Amanda D Henderson, Anthony C Arnold, Laura Bonelli, Heather E Moss, Sylvia Elizabeth Villarreal Navarro, Tanyatuth Padungkiatsagul, Hadas Stiebel-Kalish, Itay Lotan, Adi Wilf-Yarkoni, Helen Danesh-Meyer, Stefan Ivanov, Saif Huda, Mirasol Forcadela, David Hodge, Pascale Poullin, Julie Rode, Caroline Papeix, Samir Saheb, Marine Boudot de la Motte, Catherine Vignal, Yael Hacohen, Julie Pique, Elisabeth Maillart, Romain Deschamps, Bertrand Audoin, Romain Marignier
PURPOSE: To evaluate the effectiveness of plasma exchange (PLEX) for optic neuritis (ON). METHODS: We conducted an international multicenter retrospective study evaluating the outcomes of ON following PLEX. Outcomes were compared to raw data from the Optic Neuritis Treatment Trial (ONTT) using a matched subset. RESULTS: A total of 395 ON attack treated with PLEX from 317 patients were evaluated. The median age was 37 years (range 9 to 75) and 71% were female...
February 21, 2023: American Journal of Ophthalmology
#14
JOURNAL ARTICLE
Ofir Cohn, Gal Yankovitz, Naama Peshes-Yaloz, Yael Steuerman, Amit Frishberg, Rachel Brandes, Michal Mandelboim, Jennifer R Hamilton, Tzachi Hagai, Ido Amit, Mihai G Netea, Nir Hacohen, Fuad A Iraqi, Eran Bacharach, Irit Gat-Viks
When challenged with an invading pathogen, the host-defense response is engaged to eliminate the pathogen (resistance) and to maintain health in the presence of the pathogen (disease tolerance). However, the identification of distinct molecular programs underpinning disease tolerance and resistance remained obscure. We exploited transcriptional and physiological monitoring across 33 mouse strains, during in vivo influenza virus infection, to identify two host-defense gene programs-one is associated with hallmarks of disease tolerance and the other with hallmarks of resistance...
December 5, 2022: Cell Systems
#15
JOURNAL ARTICLE
Rosa Cortese, Ferran Prados Carrasco, Carmen Tur, Alessia Bianchi, Wallace Brownlee, Floriana De Angelis, Isabel De La Paz, Francesco Grussu, Lukas Haider, Anu Jacob, Baris Kanber, Lise Magnollay, Richard S Nicholas, Anand Trip, Marios Yiannakas, Ahmed T Toosy, Yael Hacohen, Frederik Barkhof, Olga Ciccarelli
BACKGROUND AND OBJECTIVES: Relapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination...
January 17, 2023: Neurology
#16
COMMENT
Omar Abdel-Mannan, Olga Ciccarelli, Yael Hacohen
No abstract text is available yet for this article.
September 1, 2022: JAMA Network Open
#17
JOURNAL ARTICLE
Micha Hacohen, Orit E Stolar, Matitiahu Berkovitch, Odelia Elkana, Elkana Kohn, Ariela Hazan, Eli Heyman, Yael Sobol, Danel Waissengreen, Eynat Gal, Ilan Dinstein
In recent years there has been growing interest in the potential benefits of CBD-rich cannabis treatment for children with ASD. Several open label studies and one double-blind placebo-controlled study have reported that CBD-rich cannabis is safe and potentially effective in reducing disruptive behaviors and improving social communication. However, previous studies have mostly based their conclusions on parental reports without the use of standardized clinical assessments. Here, we conducted an open label study to examine the efficacy of 6 months of CBD-rich cannabis treatment in children and adolescents with ASD...
September 9, 2022: Translational Psychiatry
#18
MULTICENTER STUDY
John J Chen, Saif Huda, Yael Hacohen, Michael Levy, Itay Lotan, Adi Wilf-Yarkoni, Hadas Stiebel-Kalish, Mark A Hellmann, Elias S Sotirchos, Amanda D Henderson, Sean J Pittock, M Tariq Bhatti, Eric R Eggenberger, Marie Di Nome, Ho Jin Kim, Su-Hyun Kim, Albert Saiz, Friedemann Paul, Russell C Dale, Sudarshini Ramanathan, Jacqueline Palace, Valentina Camera, Maria Isabel Leite, Byron L Lam, Jeffrey L Bennett, Sara Mariotto, Dave Hodge, Bertrand Audoin, Elisabeth Maillart, Romain Deschamps, Julie Pique, Eoin P Flanagan, Romain Marignier
IMPORTANCE: Recent studies suggest that maintenance intravenous immunoglobulin (IVIG) may be an effective treatment to prevent relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD); however, most of these studies had pediatric cohorts, and few studies have evaluated IVIG in adult patients. OBJECTIVE: To determine the association of maintenance IVIG with the prevention of disease relapse in a large adult cohort of patients with MOGAD...
May 1, 2022: JAMA Neurology
#19
JOURNAL ARTICLE
Omar Abdel-Mannan, Ainat Klein, Anat Bachar Zipori, Liat Ben-Sira, Aviva Fattal-Valevski, Yael Hacohen, Hadas Meirson
Aquaporin-4 antibody (AQP4-Ab) Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare neuroinflammatory syndrome presenting predominantly with optic neuritis and transverse myelitis. We report a case of radiologically isolated longitudinally extensive optic neuritis in an asymptomatic 12-year-old female with positive serum AQP4-Ab, with resolution of imaging changes after immune therapy. By contrast to patients with radiologically isolated syndrome, of which some will never convert to multiple sclerosis, the pathogenicity of AQP4-Ab in the context of sub-clinical disease, supported treatment in our patient...
April 2022: Multiple Sclerosis: Clinical and Laboratory Research
#20
JOURNAL ARTICLE
Yael Hacohen, Olga Ciccarelli
No abstract text is available yet for this article.
February 10, 2022: Neurology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
